在乳腺癌中 EpCAM 和 Sox2 表达的临床病理意义。

Clinicopathologic implications of EpCAM and Sox2 expression in breast cancer.

机构信息

Pathology Department, Faculty of Medicine, Minia University, El-Minia, Egypt.

出版信息

Clin Breast Cancer. 2014 Feb;14(1):e1-9. doi: 10.1016/j.clbc.2013.09.006. Epub 2013 Sep 27.

DOI:10.1016/j.clbc.2013.09.006

PMID:24201161

Abstract

BACKGROUND

The purpose of this study was to investigate the clinicopathologic significance of EpCAM and Sox2 expression in breast cancer and to study their correlation during breast cancer progression.

PATIENTS AND METHODS

EpCAm and Sox2 expression were assessed using immunohistochemistry in ductal carcinoma insitu (DCIS), invasive breast cancer (IBC) and matched lymph node metastasis (LNM), if present.

RESULTS

EpCAM overexpression was found in 63.2% of DCIS, 72.2% of IBC and 74.4% of LNM. In IBC cases, EpCAM overexpression was associated with high grade (P < .001), large tumor size (P = .051), poor Nottingham Prognostic Index (NPI) (P = .006), histological tumor types (P = .044) and the triple negative phenotype (P = .008). LNM frequently reflected the expression phenotype of the matched primary tumors with no significant differences between LNM and their primary tumors (P = .564). Sox2 expression was detected in 47.4%, 33.3% and 54.7% of DCIS, IBC and LNM respectively. In DCIS group, Sox2 expression was significantly associated with comedo type (P = .037), negative ER (P = .012) and PR (P = .037) and the triple negative phenotype (P = .006). In IBC cases, Sox2 expression showed significant associations with high grade (P = .045), nodal spread (P = .037), poor NPI (P = .018) and the triple negative phenotype (P < .001). LNM showed significantly higher Sox2 expression rates than primary tumors (P < .001). Significant positive associations between EpCAM overexpression and Sox2 positivity in DCIS (P = .027), IBC (P = .001) and LNM (P < .001) were found.

CONCLUSION

This study emphasized the potential role of EpCAM and Sox2 in breast carcinogenesis and revealed their involvement during breast cancer progression and LN metastases.

摘要

背景

本研究旨在探讨 EpCAM 和 Sox2 在乳腺癌中的临床病理意义，并研究它们在乳腺癌进展过程中的相关性。

方法

采用免疫组织化学法检测导管原位癌（DCIS）、浸润性乳腺癌（IBC）及相应淋巴结转移（LNM）中 EpCAM 和 Sox2 的表达。

结果

在 63.2%的 DCIS、72.2%的 IBC 和 74.4%的 LNM 中发现 EpCAM 过表达。在 IBC 病例中，EpCAM 过表达与高分级（P <.001）、大肿瘤大小（P =.051）、不良的诺丁汉预后指数（NPI）（P =.006）、组织学肿瘤类型（P =.044）和三阴性表型（P =.008）相关。LNM 常反映与其原发肿瘤的表达表型，LNM 与其原发肿瘤之间无显著差异（P =.564）。在 DCIS 组中 Sox2 的表达分别为 47.4%、33.3%和 54.7%，在 IBC 组和 LNM 组中。在 DCIS 组中，Sox2 的表达与粉刺型（P =.037）、ER（P =.012）和 PR 阴性（P =.037）和三阴性表型（P =.006）显著相关。在 IBC 病例中，Sox2 的表达与高分级（P =.045）、淋巴结扩散（P =.037）、不良的 NPI（P =.018）和三阴性表型（P <.001）显著相关。LNM 的 Sox2 表达率明显高于原发肿瘤（P <.001）。在 DCIS（P =.027）、IBC（P =.001）和 LNM（P <.001）中，EpCAM 过表达与 Sox2 阳性之间存在显著的正相关。